Managers

Newly minted OMERS Growth Equity eyes long-run tech disruption

Newly minted OMERS Growth Equity eyes long-run tech disruption

Fifth Wall Ventures rakes in over $468 mln for sophomore fund

Fifth Wall Ventures has raised over $468 million for its second fund, according to an SEC filing. The target is $500 million. With offices in San Francisco and Los Angeles, Fifth Wall is a venture firm focused on tech solutions for the "built world."

The Co-operators launches fund earmarked for insurtech ventures

The Co-operators Group Ltd, a Canadian insurance and financial services co-operative, has launched a new fund to invest in insurance technology companies. The size of the fund was not disclosed. President and CEO Rob Wesseling said the fund will support The Co-operators' innovation strategy by partnering with companies that offer "cutting-edge technology and solutions to meet the changing needs and preferences of our clients." Last year, The Co-operators partnered with New York-based insurance cloud platform Slice Labs Inc to create a new digital insurance brand in Canada. It also led Slice Labs' US$20 million extended Series A financing.

Noveome Biotherapeutics nabs $15 mln Series D

Pittsburgh-based Noveome Biotherapeutics Inc, a clinical-stage biopharmaceutical company, has secured $15 million in Series D financing. The company's investors included U.S. Department of Defense and the Commonwealth of Pennsylvania and Allegheny County.

LiveOak wraps up sophomore fund at $105 mln

LiveOak Venture Partners has closed its second fund at $105 million. The Austin-based venture firm invests in early-stage startups in Texas.

Texas-focused LiveOak Venture Partners raises $105 mln second fund

Big rounds continue to drive venture capital investing in Q1

New kidney care company Strive Health grabs funding

Strive Health, a kidney care company, has raised an undisclosed amount of funding. New Enterprise Associates led the round with participation from Ascension Ventures, Town Hall Ventures and Echo Health Ventures.

RMG Global wraps up biopharma fund at $64 mln

RMG Global has closed its biopharma investment fund at $64 million. The fund is focused on biotherapeutics developed within the Israel-based FutuRx incubator, established by OrbiMed Israel, Johnson & Johnson Innovation and Takeda Ventures in cooperation with the Israel Innovation Authority.